The IMA Group Announces Acquisition of Exemplar Research, Inc.

PRESS RELEASE FROM THE IMA GROUP
November 30, 2021
Press Contacts
Brenna Harrington
706-217-7809
The IMA Group header image
TARRYTOWN, N.Y. —

The IMA Group (IMA) announced today the acquisition of Exemplar Research, Inc. (ERI), a community-based specialty research clinic with an outpatient facility serving the North Central region of West Virginia. The move marks IMA’s fourth acquisition in as many months and further broadens its access to diverse populations in underserved areas.    

ERI has therapeutic expertise in conducting vaccine, pulmonary, internal medicine, gastroenterology, infectious disease, neurology, urology, and pain trials.  With its recent acquisitions, and the company’s decentralized clinical trial network, ERI gives IMA an additional strategic location for conducting high-quality clinical trials.   

“Adding Exemplar Research to the IMA Clinical Research family allows us to continue our growth trajectory and expand our research capabilities and reach,” said Mark Weinberger, PhD, MPH, President of The IMA Group. “ERI’s experience in a wide range of important therapeutic research areas, as well as their ability to recruit subjects of all ages, further differentiates IMA’s clinical trial services.”

“Joining the national IMA network expands our clinical trial capabilities and enables a wider range of patients to participate in groundbreaking research,” commented Greg Jones, Executive Director and Co-founder of Exemplar Research. “IMA’s approach supports our commitment to ensuring clinical trials better represent the people who will ultimately use the innovative products and services being studied.”

Financial terms for the two privately held companies were not disclosed. Exemplar Research, Inc. will continue to operate under its current name, with key leadership and staff remaining in place.  

###
About

IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas.  With more than 100 sites in the IMA Clinical Trial Network, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and decentralized clinical trials that support the development of safe and effective treatments.  The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested clinical trial participants for pharmaceutical sponsors.  For more information, visit www.imaresearch.com or www.theIMAgroup.com. 

#     #    #